期刊文献+

Biological Disruptive Therapies as Counter Measures for Unpredictable Biological Insults, a Case for Successful Treatment of COVID-19

Biological Disruptive Therapies as Counter Measures for Unpredictable Biological Insults, a Case for Successful Treatment of COVID-19
下载PDF
导出
摘要 Treatment of patients with severe COVID-19, is challenging specifically when a patient carries high risk of mortality, such as old age, immune suppression or cancer. Also a patient who manifests the disease with severe symptoms, such as hypoxia, requiring supplemental oxygenation, or artificial ventilation has a poor prognosis. Here we review the scientific rationale used to design a very promising therapy based on existing literature, but in significantly different method and protocols, used to treat cases of severe COVID-19, and we conclude that although the effort on drug development has been enormous, but as of today, we do not have a therapy with specific characteristics as this protocol, to be used safely in human and yet potentially meet the expectations we would have for a so called “effective therapy”. Further clinical trials are needed to support this hypothesis and generate further hypothesis to prove the concept in larger cohort of patients. Treatment of patients with severe COVID-19, is challenging specifically when a patient carries high risk of mortality, such as old age, immune suppression or cancer. Also a patient who manifests the disease with severe symptoms, such as hypoxia, requiring supplemental oxygenation, or artificial ventilation has a poor prognosis. Here we review the scientific rationale used to design a very promising therapy based on existing literature, but in significantly different method and protocols, used to treat cases of severe COVID-19, and we conclude that although the effort on drug development has been enormous, but as of today, we do not have a therapy with specific characteristics as this protocol, to be used safely in human and yet potentially meet the expectations we would have for a so called “effective therapy”. Further clinical trials are needed to support this hypothesis and generate further hypothesis to prove the concept in larger cohort of patients.
作者 Mohammad Nezami Vicky Yamamoto Mohammad Nezami;Vicky Yamamoto(Sahel Oncology LLC, Cancer Research and Life Foundation, Research Cancer Institutes of America, Newport Beach, CA, USA;Department of Head and Neck Surgery, School of Medicine, University of Southern California (USC), Los Angeles, CA, USA)
出处 《Advances in Infectious Diseases》 2020年第3期175-183,共9页 传染病进展(英文)
关键词 COVID-19 Acute Respiratory Distress Syndrome(ARDS) Phosphoinositol 3 Kinase (Pi3K) QUERCETIN COVID-19 Acute Respiratory Distress Syndrome(ARDS) Phosphoinositol 3 Kinase (Pi3K) Quercetin
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部